This can be attributed to a potential dysregulation of neuroplasticity in patients with T2DM compared to other populations, such as patients with End Stage Renal Disease, where the elevation of S100B serum levels could be the result of the accumulation of uremic toxins [35]. This evidence concerns the gene S100B and chronic kidney disease.